Investigation of IL-33 serum levels in patients with benign and malignant salivary gland tumors
- 31 August 2018
- journal article
- research article
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 23 (1) , 61-65
Abstract
BACKGROUND: Interleukin-33 (IL-33) has been recently discovered as an influential factor in the process of tumor immunity, and is presented in cancer pathogenesis. OBJECTIVE: This study aimed to determine the serum levels of IL-33 in patients with beKeywords
This publication has 18 references indexed in Scilit:
- Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland TumorsInternational Journal of Surgical Pathology, 2016
- An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancerBritish Journal of Cancer, 2015
- Circulating IL-33 level is associated with the progression of lung cancerLung Cancer, 2015
- The role of IL-33/ST2L signals in the immune cellsImmunology Letters, 2015
- The Association of Serum IL-33 and sST2 with Breast CancerDisease Markers, 2015
- Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cellsInternational Journal of Cancer, 2013
- The paracrine effect of cancer‐associated fibroblast‐induced interleukin‐33 regulates the invasiveness of head and neck squamous cell carcinomaThe Journal of Pathology, 2013
- IL-33/ST2 axis in innate and acquired immunity to tumorsOncoImmunology, 2012
- The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’?PLOS ONE, 2008
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJournal of Clinical Investigation, 2007